ribavirin and Nausea
ribavirin has been researched along with Nausea in 14 studies
Research
Studies (14)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Gonzales, GR; Gonzalez, SA; Modi, AA; Nazario, HE | 1 |
| Abrams, GA; Afdhal, NH; Albanis, E; Bernstein, DE; Berrey, MM; Bzowej, NH; Darling, JM; Dejesus, E; Dieterich, DT; Freilich, B; Hassanein, T; Hindes, R; Hyland, RH; Jacobson, IM; Jensen, D; Kowdley, KV; Lalezari, JP; Lawitz, E; Lin, M; Mader, M; Mo, H; Muir, A; Nelson, DR; Poordad, FF; Reddy, KR; Rodriguez-Torres, M; Sheikh, AM; Sulkowski, MS; Symonds, WT | 1 |
| Agarwal, K; Bertelsen, K; Brown, RS; Buti, M; De Masi, R; De Meyer, S; Hézode, C; Horsmans, Y; Janczewska, E; Luo, D; Nyberg, L; Paraná, R; Rizzetto, M; Sievert, W; Witek, J; Zeuzem, S | 1 |
| Chan, J; Mohammad, RA; Smith, MA | 1 |
| Childs-Kean, LM; Hand, EO | 1 |
| Craft, ZN; Kamal, KM; Koerner, PH; Miller, RT; Trombatt, WD | 1 |
| Chen, H; Huang, P; Li, J; Liu, M; Wang, J; Yao, Y; Yu, R; Yue, M; Zang, F; Zhang, Y | 1 |
| Hamer, C | 1 |
| Byrnes-Blake, K; de la Torre, A; Flamm, S; Fontana, D; Freeman, J; Gordon, SC; Gray, T; Hausman, D; Hunder, NN; Lawitz, E; Lopez-Talavera, JC; Marotta, P; Muir, AJ; Shiffman, ML; Vierling, JM; Yoffe, B; Zaman, A | 1 |
| Cooper, CL; Costiniuk, CT; Mills, E | 1 |
| Schalm, SW | 1 |
| Chakrabarti, S; Collingham, KE; Fegan, CD; Holder, K; Milligan, DW; Osman, H | 1 |
| Cheson, BD; Grem, JL; Hawkins, MJ; King, SA; Rubinstein, L; Shoemaker, DD | 1 |
| Culham, CA; Hartshorn, JN; Haugh, LD; Krakoff, IR; McCormack, JJ; Newman, RA; Roberts, JD; Stewart, JA; Young, JA | 1 |
Reviews
3 review(s) available for ribavirin and Nausea
| Article | Year |
|---|---|
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Topics: Adult; Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Nausea; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nausea; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
Clinical toxicity associated with tiazofurin.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Female; Heart Diseases; Humans; Infusions, Intravenous; Leukopenia; Male; Nausea; Neoplasms; Ribavirin; Ribonucleosides; Ulcer; Vomiting | 1990 |
Trials
5 trial(s) available for ribavirin and Nausea
| Article | Year |
|---|---|
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2013 |
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Nausea; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2014 |
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.
Topics: Adult; Anorexia; Antiviral Agents; Cannabinoids; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Nausea; Retrospective Studies; Ribavirin; Treatment Outcome; Weight Loss | 2008 |
Adding ribavirin to interferon alpha-2b for chronic hepatitis C infection increased virological response and nausea.
Topics: Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nausea; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 1998 |
Other Studies
6 other study(ies) available for ribavirin and Nausea
| Article | Year |
|---|---|
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Topics: Abdominal Pain; Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Esophageal and Gastric Varices; Fatigue; Female; Fluorenes; Gastrointestinal Hemorrhage; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nausea; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
Topics: Amides; Antiviral Agents; Asthenia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Load | 2017 |
The impact of combination therapy with peginterferon alpha-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients.
Topics: Aged; Antiviral Agents; Appetite; Body Mass Index; Body Weight; Drug Therapy, Combination; Energy Intake; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires | 2008 |
Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study.
Topics: Administration, Oral; Adult; Anemia; Anemia, Aplastic; Antiviral Agents; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Male; Middle Aged; Nausea; Parainfluenza Virus 3, Human; Pilot Projects; Pneumonia, Viral; Population Surveillance; Prospective Studies; Respiratory Syncytial Virus Infections; Respirovirus Infections; Ribavirin; Transplantation Conditioning; Treatment Outcome | 2001 |
Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
Topics: Adult; Aged; Allopurinol; Antimetabolites, Antineoplastic; Creatine Kinase; Drug Administration Schedule; Drug Evaluation; Female; Headache; Hemoglobins; Humans; Hypoxanthines; Isoenzymes; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Purines; Ribavirin; Ribonucleosides; Uric Acid; Xanthine; Xanthines | 1987 |